Overview
Lobbying Costs
350,000€
Financial year: Jan 2016 - Dec 2016
Lobbyists (Full time equivalent)
0.75 Fte (2)
Lobbyists with EP accreditation
2
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Grünenthal GmbH (Grünenthal)
EU Transparency Register
67826544528-01 First registered on 14 Nov 2010
Goals / Remit
The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation.
Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a €2 billion company.
We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation.
Grünenthal is an independent, family-owned company headquartered in Aachen, Germany. We are present in 32 countries with affiliates in Europe, Latin America and the US. Our products are sold in more than 155 countries and approx. 5,500 employees are working for the Grünenthal Group worldwide. In 2016, Grünenthal achieved revenues of approx. € 1.4 bn.
More information: www.grunenthal.comMain EU files targeted
Grünenthal interests in Brussels deal with issues related to health- and pain care, pharmaceuticals, innovation, research and intellectual property.
Address
Head Office
Zieglerstraße, 6
Aachen D-52099
GERMANY -
People
Total lobbyists declared
2
Employment time Lobbyists 50% 1 25% 1 Lobbyists (Full time equivalent)
0.75
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
2 accreditations were / are live (in bold) for the selected state of 21 Feb 2018
Name Start date End Date Ms Gudula Maria Petersen 14 Jun 2018 14 Jun 2019 Mr Theodorus Norbertus Maria van Rooij 17 Oct 2017 17 Oct 2018 Ms Gudula Maria Petersen 12 May 2017 09 May 2018 Mr Theodorus Norbertus Maria van Rooij 10 Oct 2016 05 Oct 2017 Ms Gudula Maria Petersen 29 Apr 2016 29 Apr 2017 Mr Theodorus Norbertus Maria van Rooij 24 Sep 2015 19 Sep 2016 Mr Konrad Labuschagne 21 May 2014 05 Jun 2015 Mr Konrad Labuschagne 25 May 2013 21 May 2014 Mrs Kristina Barinka 02 Mar 2013 29 Mar 2014 Mr Konrad Labuschagne 19 Jun 2012 17 Jun 2013 Mr Theodorus Norbertus Maria van Rooij 24 Mar 2012 01 Dec 2012 Mrs Kristina Barinka 24 Mar 2012 01 Dec 2012 Complementary Information
In 2015 0,5 FTE -
In 2016 05 FT + 0,25 FTE
In 2017 05 FT + 0,25 FTEPerson in charge of EU relations
Mr Norbert van Rooij (Governmental Affairs and Health Policy)
Person with legal responsibility
Mr Gabriel Baertschi (Chairman of the Corporate Executive Board)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
Grünenthal is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA): http://www.efpia.eu
Grünenthal supports the platform the Societal Impact of Pain (SIP). More info can be found here: https://www.sip-platform.euMember organisations
None declared
-
Financial Data
Closed financial year
Jan 2016 - Dec 2016
Lobbying costs for closed financial year
350,000€
EU grant income for closed financial year
15,589 € (Source: This amount refers financial support received within the consortium, from the NRW authorities https://www.leitmarktagentur.nrw/lw_resource/datapool/_items/item_292/pdb_ls-1-1-020.pdf)
Other financial info
The estimate of the annual costs related to activities covered by the register is based on a percentage of the salaries of the staffers in 2016 falling under the scope of the Register, based on the proportion of employee time spent on these activities.
Furthermore we have included consultancy costs, member association fees and support of health policy related activities in Brussels. -
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
Grünenthal is active on many fronts – but its primary work (research) involvement is in the field of pain relief. For this reason, it is extremely important to us to participate in a wide variety of initiatives in this particular field.
You find an overview of our initiatives here: https://www.grunenthal.com/grt-web/Grunenthal_Group/Company/Initiatives/en_EN/115200203.jspOther activities
June 2017 Grünenthal supported the Symposium “Societal Impact of Pain” (SIP) 2017. The meeting was made possible with the support of the Maltese Ministry for Health Malta and financial support provided by the Maltese Ministry for Finance and took place under the auspices of the agenda of the 2017 Maltese Presidency of the Council of the EU. More Information you find here: https://www.sip-platform.eu/events/sip-2017
Meetings
Meetings
None declared